Benjamin R Bavinton
Overview
Explore the profile of Benjamin R Bavinton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
94
Citations
848
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chan C, Bavinton B, Wong H, Rule J, Nguyen L, Spencer S, et al.
AIDS Behav
. 2025 Jan;
PMID: 39865201
Peer support from social networks of gay, bisexual, and other men who have sex with men (GBMSM) has been recognised as a critical driver of engagement with HIV prevention. Using...
2.
King J, McManus H, Gray R, Nigro S, Sisnowski J, Dobbins T, et al.
J Int AIDS Soc
. 2024 Dec;
27(12):e26399.
PMID: 39629640
Introduction: Due to a lack of robust population denominators, Australia is unable to accurately monitor changes in the HIV epidemic for some populations. The ratio of HIV transmission relative to...
3.
Chan C, Holt M, Smith A, Broady T, MacGibbon J, Mao L, et al.
J Int AIDS Soc
. 2024 Nov;
27(11):e26398.
PMID: 39581846
Introduction: HIV pre-exposure prophylaxis (PrEP) has been publicly available since 2018 in Australia as a daily regimen. In 2019, clinical guidelines were updated to support guidance on event-driven PrEP (ED-PrEP)...
4.
Wu J, Fairley C, Grace D, Bavinton B, Fraser D, Chan C, et al.
Sex Health
. 2024 Nov;
21.
PMID: 39531373
Background Pre-exposure prophylaxis (PrEP) is a safe and effective medication for preventing HIV acquisition. We examined Australian general practitioners' (GP) knowledge of PrEP efficacy, characteristics associated with ever prescribing PrEP...
5.
Wardhani B, Grulich A, Kawi N, Prasetia Y, Luis H, Wirawan G, et al.
J Int AIDS Soc
. 2024 Oct;
27(11):e26386.
PMID: 39448551
Introduction: There are no longitudinal HIV incidence data among men who have sex with men (MSM) and transgender women (TGW) in Indonesia. We aimed to estimate HIV prevalence and incidence...
6.
Medland N, McManus H, Bavinton B, Fraser D, Traeger M, Grulich A, et al.
Lancet HIV
. 2024 Sep;
11(11):e756-e764.
PMID: 39348834
Background: HIV pre-exposure prophylaxis (PrEP) is highly effective and has been government subsidised in Australia since April, 2018. We examined HIV incidence over 5 years in a retrospective observational cohort...
7.
Holt M, Bavinton B, Calabrese S, Broady T, Clackett S, Cornelisse V, et al.
Sex Transm Dis
. 2024 Sep;
52(2):73-80.
PMID: 39316034
Background: There is growing interest in novel sexually transmissible infection (STI) prevention strategies, including doxycycline postexposure prophylaxis (doxy-PEP). We assessed interest in doxy-PEP and other STI prevention strategies among gay...
8.
Bavinton B, Schmidt H, Mills S, Phanuphak N
Sex Health
. 2024 Jun;
21.
PMID: 38833542
Long-acting injectable PrEP, particularly cabotegravir (CAB-LA), has the potential to enhance HIV prevention in Asia, and was the topic of a roundtable held in Singapore in June 2023. Despite proven...
9.
Seib K, Donovan B, Thng C, Lewis D, McNulty A, Fairley C, et al.
BMJ Open
. 2024 Apr;
14(4):e081675.
PMID: 38626958
Introduction: Gonorrhoea, the sexually transmissible infection caused by , has a substantial impact on sexual and reproductive health globally with an estimated 82 million new infections each year worldwide. antimicrobial...
10.
Fraser D, Holt M, Ong J, Bourne C, Chan C, Grulich A, et al.
AIDS
. 2024 Mar;
38(5):765-767.
PMID: 38482908
Evaluating HIV preexposure prophylaxis (PrEP) use and HIV risk events concurrently remains challenging. We developed a single question method for measuring prevention-effective adherence with PrEP in self-report questionnaires. In a...